

Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: Slovakia, minimal size of groups n = 5

EQA round: BM1/19 - Bone Markers

Dead line: 08.02.2019

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(431) Parathyroid hormone (PTH)					25							24	22	92%
Samples and groups	[pmol/L]													
Sample A		7,53	1,6	21	25							24	23	96%
(60) Roche		7,13	0,66	9,2	15	0	CVPG	7,18	0,22	23%	5,52	8,84	15	
Other					10	0							9	
								3x 1, 2x 12, 1x 29, 4x 179						
Sample B		22,0	3,8	18	25							24	22	92%
(60) Roche		21,4	1,5	6,8	15	0	CVPG	21,3	0,49	23%	16,4	26,2	15	
Other					10	0							9	
								3x 1, 2x 12, 1x 29, 4x 179						
(432) Collagen telopeptide CTx-beta					17							16	15	94%
Samples and groups	[ng/L]													
Sample A		353	23	6,5	17							16	15	94%
(60) Roche		355	21	5,9	16	1	CVPG	360	5,5	17%	298	422	16	
Other					1	0							0	
								1x 183						
Sample B		723	56	7,7	17							16	15	94%
(60) Roche		728	52	7,1	16	1	CVPG	742	12	17%	615	869	16	
Other					1	0							0	
								1x 183						
(433) P1NP					13							13	13	100%
Samples and groups	[µg/L]													
Sample A		28,2	2,3	8,1	13							13	13	100%
(60) Roche		28,2	2,3	8,1	13	0	CVPG	28,3	0,61	20%	22,6	34	13	
Sample B		187	19	9,9	13							13	13	100%
(60) Roche		187	19	9,9	13	0	CVPG	187	4,6	20%	149	225	13	
(434) Osteocalcin					17							15	13	87%
Samples and groups	[µg/L]													
Sample A		17,9	1,1	5,9	17							15	14	93%
(60) Roche		18,2	0,80	4,4	14	0	CVPG	18,1	0,21	13%	15,7	20,5	14	
Other					3	0							1	
								1x 24, 1x 29, 1x 164						
Sample B		88,4	7,9	9,0	17							15	13	87%
(60) Roche		89,0	4,8	5,4	14	0	CVPG	88,4	1,2	13%	76,9	99,9	14	
Other					3	0							1	
								1x 24, 1x 29, 1x 164						
(435) 25-hydroxyvitamin D					26							24	24	100%
Samples and groups	[nmol/L]													
Sample A		70,7	11	16	26							24	24	100%
(256) Roche (2)		73,8	6,3	8,6	19	0	CVPG	72,9	2,4	33%	48,8	97	19	
Other					7	0							5	
								3x 1, 1x 12, 1x 40, 1x 60, 1x 998						
Sample B		133	17	13	26							24	24	100%
(256) Roche (2)		138	12	8,6	19	0	CVPG	138	4,4	33%	92,4	184	19	
Other					7	0							5	
								3x 1, 1x 12, 1x 40, 1x 60, 1x 998						

st_kn_p

End of report

Printed: 19.02.2019